Targeting YAP‐p62 signaling axis suppresses the EGFR‐TKI‐resistant lung adenocarcinoma

BACKGROUND: Despite the progress of advanced target therapeutic agents and immune checkpoint inhibitors, EGFR‐TKI resistance is still one of the biggest obstacles in treating lung cancer. Clinical studies with autophagy inhibitors are actively underway to overcome drug resistance. METHODS: We used P...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Hee Sun, Lee, Da‐Hye, Kang, Da Hyun, Yeo, Min‐Kyung, Bae, Goeun, Lee, Dahye, Yoo, Geon, Kim, Ju‐Ock, Moon, Eunyoung, Huh, Yang Hoon, Lee, Sang‐Hee, Jo, Eun‐Kyeong, Cho, Sang Yeon, Lee, Jeong Eun, Chung, Chaeuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926029/
https://www.ncbi.nlm.nih.gov/pubmed/33486901
http://dx.doi.org/10.1002/cam4.3734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926029/
https://www.ncbi.nlm.nih.gov/pubmed/33486901
http://dx.doi.org/10.1002/cam4.3734

Ejemplares similares